Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol
Authors:
- 1 July 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 23 (7) , 1047-1056
Abstract
Background. Anti-drug antibodies (ADAbs) may decrease the efficacy of biologics and increase the risk of adverse events. A single positive test may not precludKeywords
This publication has 32 references indexed in Scilit:
- Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn’s diseaseScandinavian Journal of Gastroenterology, 2014
- Measuring disease activity in Crohn's disease: what is currently available to the clinicianClinical and Experimental Gastroenterology, 2014
- Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBDJournal of Crohn's and Colitis, 2013
- Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trialGut, 2013
- Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agentsInflammatory Bowel Diseases, 2012
- C‐reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post‐hoc analysis from ACCENT IAlimentary Pharmacology & Therapeutics, 2012
- The Future of Inflammatory Bowel Disease Therapy: Where Do We Go from Here?Digestive Diseases, 2012
- Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapyAlimentary Pharmacology & Therapeutics, 2011
- Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's DiseaseClinical Gastroenterology and Hepatology, 2011
- Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurementCurrent Opinion in Immunology, 2008